Twist Bioscience Corporation Noncash or Part Noncash Acquisition, Payables Assumed
Twist Bioscience Corporation (TWST) reported Noncash or Part Noncash Acquisition, Payables Assumed of $229.00 thousand for the 3-month period ending 2020-12-31, per its 10-Q filed 2022-02-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1 · last filed 2022-02-09
- Twist Bioscience Corporation noncash or part noncash acquisition, payables assumed for the quarter ending 2020-12-31 was $229.00K.
- Twist Bioscience Corporation noncash or part noncash acquisition, payables assumed for the quarter ending 2020-06-30 was -$76.00K.
- Twist Bioscience Corporation noncash or part noncash acquisition, payables assumed for the quarter ending 2019-03-31 was -$806.00K.
- Twist Bioscience Corporation noncash or part noncash acquisition, payables assumed for the quarter ending 2018-12-31 was $826.00K, a 849.43% increase year-over-year.
- Twist Bioscience Corporation noncash or part noncash acquisition, payables assumed for fiscal 2018 was $1.31M.
| Period end | Noncash or Part Noncash Acquisition, Payables Assumed 3 month | Noncash or Part Noncash Acquisition, Payables Assumed 6 month | Noncash or Part Noncash Acquisition, Payables Assumed 9 month | Noncash or Part Noncash Acquisition, Payables Assumed 12 month |
|---|---|---|---|---|
| 2020-12-31 | $229.00K 10-Q · filed 2022-02-09 | |||
| 2020-06-30 | -$76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09 | $127.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $203.00K 10-Q · filed 2021-05-07 | |||
| 2019-03-31 | -$806.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-13 | $20.00K 10-Q · filed 2020-05-13 | $812.00K derived: sum of 3 quarters · filed 2020-11-27 | $1.29M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-12-31 | $826.00K 10-Q · filed 2020-02-10 | $1.62M derived: sum of 2 quarters · filed 2020-11-27 | $2.09M derived: sum of 3 quarters · filed 2020-11-27 | $2.05M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-09-30 | $792.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-27 | $1.27M derived: sum of 2 quarters · filed 2020-11-27 | $1.22M derived: sum of 3 quarters · filed 2020-11-27 | $1.31M 10-K · filed 2020-11-27 |
| 2018-06-30 | $476.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | $429.00K derived: sum of 2 quarters · filed 2019-08-09 | $516.00K 10-Q · filed 2019-08-09 | |
| 2018-03-31 | -$47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-02 | $40.00K 10-Q · filed 2019-05-02 | ||
| 2017-12-31 | $87.00K 10-Q · filed 2019-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |